Drug Trial Radar · NCT02996110
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Dec 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Feb 2, 2017
Primary completion
Nov 23, 2021
Study completion Nov 23, 2021
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 19, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Conditions
- Advanced Cancer
Interventions
NivolumabBiological
Specified Dose on Specified Days
IpilimumabBiological
Specified Dose on Specified Days
RelatlimabBiological
Specified Dose on Specified Days
BMS-986205Drug
Specified Dose on Specified Days
BMS-813160Drug
Specified Dose on Specified Days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Per InvestigatorTime frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (assessed up to approximately 247 weeks)
- Median Duration of Response (DOR) Per InvestigatorTime frame: From first dose to the date of first documented disease progression or death due to any cause (assessed from an average of 22 weeks up to approximately 247 weeks)
- Progression Free Survival Rate (PFSR) at 24 Weeks.Time frame: 24 weeks after first treatment dose.
Locations
32 sites in 6 countries. Site status is shown where the registry gives one.
Local Institution - 0037
New Haven, Connecticut
Local Institution
Tampa, Florida
Local Institution - 0031
Augusta, Georgia
Local Institution - 0006
Chicago, Illinois
Local Institution - 0007
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Local Institution - 0011
Detroit, Michigan
Local Institution - 0008
St Louis, Missouri
Roswell Park Cancer Institute
Buffalo, New York
Local Institution - 0005
New York, New York
Local Institution - 0043
Charlotte, North Carolina
Local Institution - 0014
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Local Institution - 0002
Allentown, Pennsylvania
Hollings Cancer Center
Charleston, South Carolina
Local Institution - 0025
Nashville, Tennessee
Ut Southwestern Medical Center
Dallas, Texas
Local Institution - 0024
Charlottesville, Virginia
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington
Local Institution - 0032
Westmead, New South Wales, Australia
Monash Medical Centre Clayton
Bentleigh, Victoria, Australia
Local Institution - 0044
Linz, Upper Austria, Austria
Local Institution - 0038
Hamilton, Ontario, Canada
Local Institution - 0029
Oshawa, Ontario, Canada
Local Institution - 0035
Toronto, Ontario, Canada
Local Institution - 0034
Montreal, Quebec, Canada
Local Institution - 0030
Québec, Quebec, Canada
Local Institution
Haifa, Israel
Local Institution
Ramat Gan, Israel
Local Institution - 0010
Milan, Italy
Local Institution - 0012
Naples, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.